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Abstract
Background: A recent Cochrane Review demonstrated the remarkable lack of reliable clinical trials of migraine 
treatments for children, especially for the two most prescribed preventative treatments in the UK, Propranolol and 
Pizotifen.
Migraine trials in both children and adults have high placebo responder rates, e.g. of 23%, but for a trial's results to be
generalisable "placebo responders" should not be excluded and for a drug to be worthwhile it should be clearly
superior, both clinically and statistically, to placebo.
Methods/Design: Two multicentre, two arm double blind parallel group randomised controlled trials, with allocation 
ratio of 2:1 for each comparison, Propranolol versus placebo and Pizotifen versus placebo. The trial is designed to test 
whether Propranolol is superior to placebo and whether Pizotifen is superior to placebo for the prevention of migraine 
attacks in children aged 5 - 16 years referred to secondary care out-patient settings with frequent migraine (2-6/4 
weeks). The primary outcome measure is the number of migraine attacks during trial weeks 11 to 14.
Discussion: A strength of this trial is the participation of clinically well defined migraine patients who will also be 
approached to help with future longer-term follow-up studies.
Trial Registration: ISRCTN97360154
Background
In the last 20 years the International Headache Society
(IHS) has fostered the development of high quality
research in headache including migraine. The 2004 (2nd)
edition of the International Classification of Headache
Disorders [1] provides a framework for headache
research, including clinical trials. It is vital that trials use
this classification which has become rather more child
relevant in this last edition.
Inclusion of patients with Probable Migraine (PM), as
defined in the classification, previously called "migraine-
like headache" or "mixed headache" is vital for the trial to
be of general use to most children presenting to paedia-
tricians with severe headaches, because many general
paediatricians will be unfamiliar with the precise opera-
tional criteria for Migraine subtypes.
A recent Cochrane Review [2] has demonstrated the
remarkable lack of reliable clinical trials of migraine
treatments for children, especially for the two most pre-
scribed preventative treatments used in the UK, Propra-
nolol and Pizotifen.
For a trial's results to be generalisable it should reflect
the high placebo responder rates (around 23% [3]) typi-
cally found and not exclude "placebo responders". In
addition for a drug to be worthwhile it should be clearly
superior, both clinically and statistically, to placebo.
The clinical course of migraine is especially difficult to
predict in children. Migraine will come for weeks,
months or a few years then remit for months or years,
sometimes returning unpredictably later on. Long term
follow-up is difficult and studies have demonstrated this
variability [4].
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The aim of this trial is to confirm or refute superiority
of Propranolol to placebo and of Pizotifen to placebo for
the prevention of migraine attacks in children aged 5 - 16
years referred to secondary care out-patient settings with
frequent migraine (2-6/4 weeks).
Both the active trial treatments or "Investigational
Medicinal Products" (IMPs), Propranolol and Pizotifen
have been in common clinical use for this indication in
children for over 20 years. The trial does not therefore
expose this group of patients to a new therapeutic risk,
but will systematically evaluate efficacy and adverse
events. The results will ascertain if one or both are supe-
rior to placebo in the prevention of migraine in children,
and quantify other useful clinical outcomes such as qual-
ity of life, school attendance, any prolonged benefit after
drug withdrawal, and adverse effects.
Methods/Design
Study design
Two simultaneous multicentre parallel group double-
blind randomised placebo controlled trials of Propranolol
and Pizotifen.
Setting
Secondary care paediatric headache or neurology clinics.
Participants
Inclusion criteria
1. age 5 years 0 months to 16 years 11 months
2. with Migraine with Out aura (MO), Migraine with 
Aura (MA), Probable Migraine (PM) as defined by 
IHS [1] (see Appendix E),
3. with 2 to 6 migraine or probable migraine attacks/4 
weeks by history during the previous 3 months
4. and 2 to 6 migraine or probable migraine attacks/4 
weeks during the 4 week run-in
5. and treating paediatrician and parent/guardian and 
child or young person believe the attacks are cur-
rently frequent and severe enough to merit a try of 
twice daily preventative medication
6. Satisfactory completion of headache diary during 
the run-in period at discretion of the investigator
Exclusion criteria
1. Asthma, bronchospasm or nocturnal or exercise 
induced cough or wheeze within the last 12 months 
or currently on daily asthma preventative treatment
2. children under paediatric cardiology review, at the 
discretion of their paediatric cardiologist, e.g. if Pro-
pranolol or Pizotifen were contraindicated
3. children with any of the following: uncontrolled 
heart disease, the presence of second or third degree 
heart block, in cardiogenic shock, bradycardia, severe 
peripheral arterial disease, metabolic acidosis, sick 
sinus syndrome, untreated phaeochromocytoma, 
prone to hypoglycaemia (e.g. after prolonged fasting) 
or Prinzmetal's angina.
4. previous severe adverse event probably related to 
Propranolol or Pizotifen
5. on Propranolol, another beta-blocker, Pizotifen or 
Cyproheptidine in the last 3 months
6. currently in or have been in another prospective 
drug trial in the last 3 months
7. fewer than 2 or more than 6 eligible attacks during 
the 4 week run-in, and stay excluded for 3 months at 
least
8. child or family unable to identify their migraine or 
probable migraine headaches confidently (as may 
happen with some patients with both mild headaches 
and migraine on different days, e.g. with chronic daily 
headache [15 or more headache days/month]).
9. females of child bearing potential who are not using 
a reliable contraceptive strategy such as abstinence, 
barrier methods, oral contraceptive pills and contra-
ceptive injections. See Pregnancy section below.
10. Informed consent not given by parents/guardian, 
or assent/consent not given by patient
Interventions
Propranolol
A non-selective beta-blocker which crosses the blood-
brain barrier exerting central as well as peripheral effects
and which has been used in migraine prevention since
the 1960s [5]. It is generally well tolerated but in high
dose can be associated with fatigue or sleep disturbance.
It can also cause bronchospasm and exacerbate asthma.
Pizotifen
An antihistamine with histamine-1 antagonist and sero-
tonin (5-HT2) antagonist properties that is structurally
related to the tricyclic antidepressants. It has been used
for over 20 years in the United Kingdom for migraine
prophylaxis in children, young people and adults. It is
generally well tolerated but can cause drowsiness, so it is
commonly given as a once a day evening dose. Other
adverse effects include increased appetite and weight
gain.
Placebo
Both liquid and tablet formulations of the placebo will be
manufactured using the same excipients used in the
active formulation of the drugs minus the active ingredi-
ents. The placebo, Propranolol and Pizotifen tablets are
matched in appearance; the liquid placebo matches the
liquid Propranolol in appearance and taste but the liquid
Pizotifen has a slightly different flavour.
All participants will be offered a choice of liquid or tab-
let preparations of the trial treatments. Because Pizotifen
only has an evening dose, while Propranolol is given twice
daily, to maintain blinding participants in the Propranolol
and placebo arms will receive morning and evening dosesSilcocks et al. Trials 2010, 11:71
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from separate bottles; those in Pizotifen arm will take a
morning placebo dose and an active evening dose (also
from separate bottles).
For both active arms in this trial, starting, titration and
age specific maintenance doses are consistent with the
recommendations in "Medicines for Children" [6] and the
new "British National Formulary (BNF) for children" [7]
for 80% of participants by standard growth charts for the
tablet preparations. The maximum dose of the liquid
preparation is less to comply with World Health Organi-
sation (WHO) recommendations on maximum intake of
propylene glycol (used as a preservative for the liquid
preparation of Propranolol).
Concomitant therapy
Permitted medication
Any other regular medication (apart from Propranolol or
other beta blocker, Pizotifen or Cyproheptidine in the 3
months before recruitment)
Other migraine preventative medication should nor-
mally be withdrawn first, but it may be continued as long
as the dose does not change during the 12 week assess-
ment.
Rescue medication and additional treatment(s)
All participants will be given an individual rescue treat-
ment plan for migraine headaches, depending on their
and their paediatrician's experience and preference. All
rescue treatments used and their doses and effects will be
recorded in the diary during the 4 weeks baseline assess-
ment block 1 and the assessment blocks 2, 3 and 4 (weeks
11-14, 25-28, 37-40).
Restrictions
Rizatriptan should be avoided by the trial participants
while taking the trial treatments and for 5 days after stop-
ping the trial treatments, because of a drug interaction
with Propranolol.
Different non-steroidal anti-inflammatory drugs
(NSAIDs) should not be used together. Aspirin should be
avoided in children under 16 years. Use of any over-the-
counter remedies will be checked by the research nurse.
Compliance
This will be assessed in 2 ways:
1) by verbally questioning the participant and parent/
guardian at visits as to roughly how often a week a 
dose is missed. The % compliance is defined as 100 - 
% missed doses.
2) by examination of returned medication bottles, and 
measurement of the observed residual tablet numbers 
or residual liquid volumes. Missed doses by tablet 
number or volume will be expressed as:.
S = amount supplied,
R = amount returned
P = amount planned to be taken
The level of acceptable compliance with study medica-
tion will be set at >50% on both measures for the main
outcome assessment period (weeks 11-14).
Criteria for terminating trial
The study may be stopped as a whole because of a regula-
tory authority decision, change in opinion of the REC or
overwhelming evidence of efficacy/inefficacy, safety con-
cerns or issues with trial conduct at the discretion of the
Sponsor.
Recruitment at a centre may be stopped particularly for
reasons of low recruitment, protocol violation or inade-
quate data recording.
Hypotheses
Primary hypothesis
• To test whether Propranolol or Pizotifen are supe-
rior to placebo for the prevention of migraine attacks 
in children aged 5 - 16 years old with frequent 
migraine (2-6/4 weeks), who are referred to second-
ary care out-patient settings.
Secondary hypotheses
• To test whether any therapeutic effect out lasts the 
period of drug administration.
• To test whether a dose (in mg/kg/day) - response 
relationship exists at the doses used.
• To test whether active treatment improves partici-
pation by school attendance, and parent/guardian 
time off work, and health related and non-health 
related quality of life, and health status.
• To estimate cost-effectiveness if either active treat-
ment proves superior to placebo.
Sample size
The number of attacks per month is assumed to follow an
over-dispersed Poisson distribution. A mean attack rate
in the last month of treatment of 3 episodes with variance
of 4 was assumed for the placebo arms based on the
review of Victor & Ryan (2003) [2].
The sample size for the primary endpoint was esti-
mated using formula 9.13 on page 176 of Machin et al [8]
assuming a 33% reduction in the attack rate in the active
arms. This formula gives the total number of attacks that
must be observed based on a Poisson distribution, and
this was divided by 2.5 (average number of attacks per
person) to give the total number of participants in each
study.
The over-dispersion in comparison with a Poisson dis-
tribution was allowed for by multiplying the required
number of participants based on the standard formula by
a factor of 1.33.
%
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The sample size estimates for each trial assumed a
power of 80% and 5% two-sided significance, with a 2:1
allocation of active: placebo treatment within each trial.
On these assumptions the required sample size is 226
evaluable participants for each trial, i.e. 452 in total, to
detect a reduction in mean attack rate in both arms from
3 to 2 per month.
The target of 600 for recruitment also leaves a margin
for drop out of up to 25% (=1-452/600) for the primary
outcome but only 2% (=1-588/600) for the proportion of
responders outcome.
Randomisation and blinding
The randomisation will be based on a computer gener-
ated pseudo-random code using random permuted
blocks of randomly varying size, created by the Notting-
ham Clinical Trials Unit (CTU) in accordance with their
standard operating procedure (SOP) and held on a secure
server. The randomisation proceeds in two stages: firstly
a randomisation to one trial or the other; secondly a ran-
domisation within each trial to active or placebo arm.
The randomisation within each trial will be stratified by
age (5-11 years vs 12-16 years), type of migraine (two cat-
egories) and recruiting centre (10 centres).
Investigators will access the treatment allocation for
each participant by means of a remote, internet-based
randomisation system developed and maintained by the
Nottingham CTU. The sequence of treatment allocations
will be concealed until interventions have all been
assigned and recruitment, data collection, and all other
trial-related assessments are complete.
Procedures and observations
Consent
The process for obtaining participant informed consent
or assent and parent/guardian informed consent will be
in accordance with the REC guidance, and Good Clinical
Practice (GCP) and any other regulatory requirements
that might be introduced.
Potential participants will be identified in clinic based
on their clinical diagnosis and history of migraine or
probable migraine attack frequency for the previous 3
months. If the potential participant and their parent/
guardian are willing to participate but cannot estimate
the migraine attack frequency in the previous 3 months
they will be given a standard headache diary to complete
over the next 3 months, and appropriate advice and treat-
ment will be given as is normal practice.
In the event of their withdrawal data collected so far
will not be erased and will be used in the final analyses
where appropriate (this will be explained in the Partici-
pant and Parent/Guardian Information Sheets).
Baseline measurements
1. A standard headache diary will be completed by the 
participant and their parent/guardian. This is adapted 
for the trial from a migraine clinic diary developed by 
the British Paediatric Neurology Association's 
(BPNA's) Governance & Audit group [9].
2. Headache intensity scale [10] - a four point self-
rated scale (assisted if needs be by the parent/guard-
ian). This is the functionally based scale recom-
mended by the IHS to assist in diagnosis, monitoring 
treatment clinically and in trials.
3. Pediatric Migraine Disability Assessment Scale 
(PedMIDAS), a standardised validated health-related 
quality of life scale for children with migraine [11].
4. Generic Child Quality of Life Measure (GCQ10), a 
standard validated non-health related quality of life 
scale for children [12].
5. EQ-5D [13], a standardised validated health out-
come measure providing a simple descriptive profile 
and a single index value for health status. For parents/
guardians and participants aged 12-16 years old.
6. Child-friendly EQ-5D [14] For younger partici-
pants; a child friendly version of EQ-5D has been 
developed and will be used during the trial for partic-
ipants aged 7-11 years.
7. UK Proxy EQ-5D [15]
8. Age, sex, height, weight, blood pressure and heart 
rate at baseline and at all clinical visits
9. Parent's/guardian's stage at leaving full-time educa-
tion
10. Full post code (to derive deprivation score for area 
of residence).
11. Office of National Statistics (ONS) self-coded NS-
SEC of one parent/guardian [16]
Outcome measurements
Primary outcome
The number of migraine attacks during weeks 11 to 14
from randomisation, as recorded in the participant diary,
with an attack being defined as in the IHS International
Classification of Headache Disorders [10].
Secondary outcomes
Efficacy 1. Response, defined as a 50% or greater reduc-
tion in number of attacks during weeks 11 to 14; 25 to 
28; 37 to 40, relative to baseline, as recorded in the 
participant diary.
2. Headache intensity; headache intensity will be 
measured on the standard 4 point scale [10]. As 
migraine headache is usually moderate or severe 
(with additional features), mild headaches will not be 
recorded, unless they are associated with sufficient 
additional features to meet the diagnostic criteria for 
migraine attack. Headache intensity as experienced 
during the worst part of the migraine attack will be 
averaged during weeks 11 to 14 for each participant.
3. Use of rescue medication, defined as the number 
of rescue doses taken during weeks 11 to 14, as 
recorded in the participant diary.Silcocks et al. Trials 2010, 11:71
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4. School attendance, defined as % of school half 
days attended during weeks 11 to 14, as recorded by 
diary.
5. Recalled Attack Frequency: participants reply at 
visit 6 to "How many migraine attacks did you have in 
the 4 week assessment block (weeks 11 to 14)?" They 
may discuss with their parents/guardian and look at 
their diary if they wish. This will help in imputing 
missing values for those who can provide no diary 
information.
6. Quality of life & functional outcomes using:
6.1 the health-related quality of life tool PedMI-
DAS;
6.2 the non-health-related Generic Child Quality 
of Life measure GCQ.
Health Economics Sufficient data to allow cost effective-
ness comparisons from NHS and family perspectives will
be collected but not analysed at this stage. If one or other
active treatments proves effective in comparison to pla-
cebo, then separate funding for a formal cost comparison
and cost effectiveness study will be sought.
1. Parent's/guardian's time off work mainly related to 
child's migraine, for those in full time paid employ-
ment, or pro-rata for those in part-time paid employ-
ment, during weeks 11 to 14, as recorded in the 
participant diary.
2. Costs of Propranolol, Pizotifen, and placebo (study 
medications)
3. Cost of rescue medications
4. Number and length of emergency hospital admis-
sions and Emergency Department attendances, and 
non-trial hospital and GP surgery appointments, 
related to migraine, with dates and place will be 
recorded in the participant diaries so the cost of 
investigations can be determined later
5. Cost of "child half days off school" (4 above)
6. EQ-5D for parents/guardian and participants aged 
12-16 years; UK Proxy EQ-5D for younger partici-
pants.
Adverse events
Safety and tolerability variables
These include:
1. Adverse Event (AE) reports:
a) spontaneous,
b) elicited by routine enquiry using the AE check 
list,
c) findings from physical and neurological exami-
nations
2. Vital signs: Blood Pressure, Heart Rate, Weight and 
Height.
3. Participant's wish to continue (or parent/guardian's 
where child unsure) with allocated trial medication 
after week 14.
4. Time until withdrawal from allocated trial medica-
tion, from randomisation to end of week 14. Reasons 
for withdrawal will be recorded in CRF.
Follow up procedures
Participants in all three groups will follow the same
schedule of study visits up to the end of the trial, regard-
less of their compliance with the trial medication. Screen-
ing & baseline assessments will be performed during
visits 1-3, with a 4 week "run-in" ending in randomisation
at visit 2 and start of trial treatment at visit 3. Visits 4-6
will take place during the 2 week dose escalation period,
12 week maintenance and 2 week down-titration phases.
Visits 7 & 8 will take place during a 3 month blinded off-
treatment phase, visit 9 during a 3 month unblinded fol-
low-up with visit 10 marking the end of the Trial, at
which point there will be an option to consent for a possi-
ble future follow-up study, (Figure 1).
Data Monitoring Committee (DMC)
An independent Data Monitoring Committee (DMC) will
evaluate the outcome and safety data in the context of the
overall trial and the currently existing information about
the study drugs. No formal interim analyses for efficacy
are planned. For these "administrative" analyses, informal
Haybittle-Peto type boundaries [17,18] will be adopted
for efficacy to permit the DMC to break the blind if it
wishes, with negligible effect on the properties of the final
analysis
Types of Analyses
The primary efficacy parameter will be the relative attack
rate between the two treatment arms and their placebo
arms, estimated by a Poisson regression model. The
model will include terms to account for treatment arm,
stratification variables and other covariates (baseline fre-
quency of attacks, prior Triptan use and whether treat-
ment naïve). The anticipated over- dispersion will be
accounted for by estimation of robust standard errors.
The analysis will be performed on the full analysis set
(following the intention to treat principle). For the pri-
mary efficacy analysis the statistical test will be two-sided
at a nominal 5% two-sided significance level (see sample
size justification).
Secondary outcomes All secondary endpoints will be
analysed using analysis of covariance, logistic regression
or Poisson regression as appropriate. Secondary analyses
will include a repea ted measures analysis of the attack
frequency at different time points (11-14 weeks; 25-28
weeks; 37-40 weeks from randomisation). Headache fre-
quency will also be analysed with respect to the mean
mg/kg/day dose for the active treatments for each partici-
pant during this period.
Again, terms to account for treatment arm, stratifica-
t i o n  v a r i a b l e s  a n d  c o v a r i a t e s  w i l l  b e  i n c l u d e d  i n  t h e
model with allowance for over-dispersion of binary/count
d a t a .  T i m e  t o  e v e n t  d a t a  w i l l  b e  h a n d l e d  b y  s u r v i v a lSilcocks et al. Trials 2010, 11:71
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regression. All secondary endpoints will be analysed only
in the full analysis set.
For the secondary analyses (excluding cost analyses),
tests and confidence intervals will also be two-sided and
performed at the 5% significance level. No adjustment for
multiple testing will be performed.
Adverse events
All adverse events will be listed. Treatment-emergent AEs
(defined as AEs which first develop or which worsen after
the start of trial treatment) will be summarised by treat-
ment, severity and relationship to treatment.
In addition the frequency (number of AEs and number
of patients experiencing an AE) of treatment-emergent
AEs will be summarised using the Medical Dictionary for
Regulatory Activities [19] (MedDRA v 9.1 or later) by pri-
mary body system and preferred term.
Physical and neurological findings at baseline and any
changes occurring during treatment will be listed.
Vital signs will be listed and summarised, together with
changes from baseline.
Treatment compliance
Treatment compliance will be summarised by treatment
group and time interval since randomisation.
Success of blinding
This will be assessed in participants, parents/guardian
and investigators by a two-part question at the week 29-
30 visit, just prior to un-blinding. The first part will ask
whether the participant was believed to have received an
active treatment or placebo. The second question will be
asked only if the answer to the first question was "active",
and will ask which active treatment was thought to have
been given. Responses to both questions will include a
"don't know" category, and the analysis will correct for
guessing.
Procedures for missing data
A major goal of this study is to obtain virtually complete
follow-up. The research nurses will ensure this as far as
possible by home visits and close telephone/texting/email
contact. No missing values are expected for the key base-
line covariates because these data must be submitted
prior to randomisation.
Missing covariate and response values will be handled
by multiple imputation using chained equations, by
means of the Stata add-in module ice [20]. In particular
the imputation for missing response data during the final
4 weeks will incorporate information on earlier baseline
response data and other variables thought likely to
Figure 1 Patient and family involvement over time.Silcocks et al. Trials 2010, 11:71
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account for the missing data. A sensitivity analysis in
which missing outcome data are assumed to be missing
not at random will also be performed for the primary out-
come and for response.
Ehtical approval
The protocol has been given full ethical approval by the
Trent Research Ethics Committee (Reference: 09/H0405/
19). It is fully compliant with the Helsinki Declaration.
Discussion
The protocol design posed some particular challenges.
The funding brief was for a 3 arm trial of Propranolol,
Pizotifen, and Placebo. For statistical and operational rea-
sons we are technically undertaking 2 parallel 2-arm tri-
als, but blinding will make it indistinguishable to
participants and local investigators from a 3 arm trial.
This way if there is a problem with one trial the other can
continue un-hindered.
We undertook several consumer involvement exercises,
with help from the Medicines for Children Research Net-
work (MCRN), and it was clear that keeping participants
and their parents/guardians blinded for up to 2 years after
their participation was not acceptable and could present a
significant barrier to recruitment and retention. Partici-
pants and their families were content to be blinded dur-
ing the trial treatment phase, but wanted to know what
the treatment had been as soon as possible afterwards, to
i n f o r m  f u t u r e  t r e a t m e n t  d e c i s i o n s .  W e  w e r e  k e e n  t o
maintain the blinding for as long as possible to avoid
investigators being biased in their approach to potential
participants, e.g. by being biased by preliminary results
against one of the active treatments. Also we felt that the
long-term assessments would be compromised if they
were undertaken unblinded. As a compromise, and tak-
ing note of consumers concerns, we decided to unblind at
visit 8 (week 29/30) see Figure 1. Consumers at the focus
group were supportive of this delay in unblinding.
We were keen to develop a protocol particularly suited
to children and young people. In contrast to adult partici-
pants, they often express fear and avoidance of medical
settings and procedures, although they are usually curi-
ous and supportive of clinical research in general and are
often remarkably altruistic. With this in mind we mini-
mised the invasive procedures commonly undertaken in
trials: there are no blood tests and only routine out-
patient procedures. Most contacts with the participants
will be by home visits by research nurses, or by phone
call, with hospital visits approximately every 3 months, so
that approximately 1 additional visit over the year is
anticipated. We needed a liquid formulation, as younger
children would be unable to swallow tablets. However, we
decided to offer participants the choice of liquid or tab-
lets as our consumer involvement work suggested that
many young people of secondary school age (teenagers)
did not want to take liquid preparations, and that would
prove a barrier to recruitment. Tablet and liquid formula-
tion concentrations were such that the numbers of tablets
taken were the same for Propranolol, Pizotifen, placebo,
during titration, maintenance and withdrawal, phases as
were the volumes of liquid formulations.
Being able to offer participants tablets also mitigates
the problem posed by the maximum ceiling dose caused
by the propylene glycol (see "interventions section above)
in the Propranolol liquid. We anticipate that most partici-
pants will take tablets because migraine is more common
in secondary school aged young people than younger
children.
We considered blinding essential in this definitive
study, and ideally wanted full blinding of participants,
their parents/guardian, their paediatrician/local investi-
gator and research nurse, and trial statistician, for which
trial the participants were in (Propranolol, or Pizotifen),
as well as within each trial (active vs placebo). To avoid
sleepiness commonly seen with Pizotifen we decided that
Pizotifen would only be given at bedtime (which is fre-
quent routine clinical practice), and to keep the blind a
placebo dose is given in the mornings. Families therefore
are given a supply of morning doses as well as a supply of
evening doses, and the importance of using the correct
supply at the correct time will be emphasised by the
research nurses.
Also rather than over encapsulation we opted to manu-
facture identically looking tablets of Propranolol, Pizo-
tifen and placebo, as we feared children or their parents
would deliberately unblind themselves out of curiosity, or
by accident. If this were to happen in a significant propor-
tion of participants the trial could be undermined. How-
ever, manufacturing tablets created other problems and
increased costs and delays.
Propranolol and Pizotifen have been widely used for
migraine in children for many years and so the exposure
in this trial is relatively low risk.
We are also making a special effort to allow for effects
of missing values of the primary response variable and
covariates through use of multiple imputation.
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